Highlight
1. The ENCIRCLE trial demonstrates that percutaneous transseptal TMVR with the SAPIEN M3 system provides sustained near-complete mitral regurgitation reduction at 2 years in patients unsuitable for surgery or edge-to-edge repair.
2. Significant improvements in patients’ functional status and health-related quality of life were maintained, with 87% in NYHA class I/II at 2 years.
3. The composite rate of all-cause mortality or heart failure hospitalization at 2 years was 35.6%, with manageable rates of stroke, valve thrombosis, and hemolysis.
4. No clinically significant left ventricular outflow tract obstruction was observed, underscoring the safety of the fully percutaneous transseptal approach.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
